DeNardo GL - Search Results

1

Radiation dosimetry for radionuclide therapy in a nonmyeloablative strategy.

DeNardo GL, Siantar CL, DeNardo SJ. DeNardo GL, et al. Among authors: denardo sj. Cancer Biother Radiopharm. 2002 Feb;17(1):107-18. doi: 10.1089/10849780252824127. Cancer Biother Radiopharm. 2002. PMID: 11915167 Review.

2

Impact of interpatient pharmacokinetic variability on design considerations for therapy with radiolabeled MAbs.

DeNardo G, Yuan A, Goldstein D, Richman C, O'Donnell R, Shen S, Hartmann Siantar C, DeNardo S. DeNardo G, et al. Cancer Biother Radiopharm. 2003 Apr;18(2):231-7. doi: 10.1089/108497803765036409. Cancer Biother Radiopharm. 2003. PMID: 12804049

3

Dose intensified molecular targeted radiotherapy for cancer-lymphoma as a paradigm.

DeNardo G, DeNardo S. DeNardo G, et al. Semin Nucl Med. 2010 Mar;40(2):136-44. doi: 10.1053/j.semnuclmed.2009.10.005. Semin Nucl Med. 2010. PMID: 20113681 Review.

4

Rationales, evidence, and design considerations for fractionated radioimmunotherapy.

DeNardo GL, Schlom J, Buchsbaum DJ, Meredith RF, O'Donoghue JA, Sgouros G, Humm JL, DeNardo SJ. DeNardo GL, et al. Among authors: denardo sj. Cancer. 2002 Feb 15;94(4 Suppl):1332-48. doi: 10.1002/cncr.10304. Cancer. 2002. PMID: 11877764 Free article.

5

Treatment planning for molecular targeted radionuclide therapy.

Siantar CH, Vetter K, DeNardo GL, DeNardo SJ. Siantar CH, et al. Among authors: denardo sj, denardo gl. Cancer Biother Radiopharm. 2002 Jun;17(3):267-80. doi: 10.1089/10849780260179233. Cancer Biother Radiopharm. 2002. PMID: 12136519 Review.

6

Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts.

Burke PA, DeNardo SJ, Miers LA, Lamborn KR, Matzku S, DeNardo GL. Burke PA, et al. Among authors: denardo sj, denardo gl. Cancer Res. 2002 Aug 1;62(15):4263-72. Cancer Res. 2002. PMID: 12154028

7

Enhanced therapeutic index of radioimmunotherapy (RIT) in prostate cancer patients: comparison of radiation dosimetry for 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-peptide versus 2IT-DOTA monoclonal antibody linkage for RIT.

DeNardo SJ, DeNardo GL, Yuan A, Richman CM, O'Donnell RT, Lara PN, Kukis DL, Natarajan A, Lamborn KR, Jacobs F, Siantar CL. DeNardo SJ, et al. Among authors: denardo gl. Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3938S-44S. Clin Cancer Res. 2003. PMID: 14506192

8

Evaluation of a cathepsin-cleavable peptide linked radioimmunoconjugate of a panadenocarcinoma MAb, m170, in mice and patients.

DeNardo GL, DeNardo SJ. DeNardo GL, et al. Among authors: denardo sj. Cancer Biother Radiopharm. 2004 Feb;19(1):85-92. doi: 10.1089/108497804773391720. Cancer Biother Radiopharm. 2004. PMID: 15068616

9

Enhancement of the therapeutic index: from nonmyeloablative and myeloablative toward pretargeted radioimmunotherapy for metastatic prostate cancer.

DeNardo SJ, Richman CM, Albrecht H, Burke PA, Natarajan A, Yuan A, Gregg JP, O'Donnell RT, DeNardo GL. DeNardo SJ, et al. Among authors: denardo gl. Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7187s-7194s. doi: 10.1158/1078-0432.CCR-1004-0013. Clin Cancer Res. 2005. PMID: 16203820

10

Implantation of different malignant human cell lines in an athymic mouse does not alter success and growth rates of either xenograft.

Miers L, DeNardo SJ, Lamborn K, DeNardo GL. Miers L, et al. Among authors: denardo sj, denardo gl. Cancer Biother Radiopharm. 2005 Dec;20(6):614-9. doi: 10.1089/cbr.2005.20.614. Cancer Biother Radiopharm. 2005. PMID: 16398613

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

517 results

Search Page

Filters